Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 29 May 2019, 09:05 HKT/SGT

Source: Eisai
Eisai to Present Latest Data on Lemborexant including Integrated Analysis of Phase III Clinical Studies at 33rd Annual Sleep Meeting

Tokyo, May 29, 2019 - (JCN Newswire) - Eisai Co.,Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") today announced that latest information on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of multiple sleepwake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) will be presented at the 33rd Annual Meeting of the Associated Professional Sleep Societies (SLEEP 2019), from June 8 to 12 in San Antonio, Texas, the United States.

Eight posters including the integrated analysis of lemborexant's effects on daily function and disease severity as well as sleep onset and sleep maintenance for the combined 1,955 patient population of two pivotal clinical Phase III studies, SUNRISE 1 (Study 304) and SUNRISE 2 (Study 303) in insomnia disorders, and an evaluation of results on respiratory function after administration of lemborexant in elderly and mild obstructive sleep apnea, and the latest pre-clinical data on ISWRD will be presented.

Lemborexant acts on the orexin neurotransmitter system and is believed to regulate sleep and wake by controlling arousal without affecting awakening by external stimuli, and is being developed for the treatment of multiple sleep-wake disorders including insomnia disorder. In December 2018 and March 2019, new drug applications seeking approval of lemborexant for use in the treatment of insomnia disorder were submitted in the United States and Japan, respectively. For the ongoing clinical studies, please visit

Through the development of lemborexant, Eisai is aiming to bring to patients suffering from sleep-wake disorders a new treatment option to improve their ability to fall and stay asleep and wake without impairing the next morning, and is striving to further contribute to satisfying unmet medical needs and improve the benefits to patients and their families.

  • Presentations for Lemborexant:
    Poster session: P18, Presentation date: Monday June 10, 5:15pm - 7:15pm (local time)
  Presentation Title
Poster Number: 102
Abstract: 0367
Lemborexant Treatment for Insomnia: Six-month Safety
Poster Number: 105
Abstract: 0368
Efficacy and Tolerability of Lemborexant in Female and Male Subjects With Insomnia
Poster Number: 106
Abstract: 0369
Effect of Lemborexant on Sleep Architecture in Older Adults With Insomnia Disorder
Poster Number: 107
Abstract: 0370
Patient-Reported Sleep Onset and Sleep Maintenance: Pooled Analyses of Lemborexant Phase 3 Studies
Poster Number: 108
Abstract: 0371
Lemborexant Treatment for Insomnia in Phase 3: Impact on Disease Severity
Poster Number: 103
Abstract: 0429
Respiratory Safety of Lemborexant in Adult and Elderly Subjects With Mild Obstructive Sleep Apnea
Poster Number: 104
Abstract: 0430
Respiratory Safety of Lemborexant in Healthy Adult and Elderly Subjects
Poster Number: 022
Abstract: 0056
SAMP8 Mice as a Preclinical Model for Irregular Sleep-Wake Rhythm Disorder and Efficacy of the Dual Orexin (Hypocretin) Receptor Antagonist Lemborexant

Separate from the poster presentations, Eisai will host a symposium, an interactive dialogue on insomnia diagnostic and therapeutic decision making, which will be held on Sunday, June 9, from 6:15pm – 8:30pm (local time).

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.

May 29, 2019 09:05 HKT/SGT
Topic: Press release summary
Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

July 19, 2019 12:00 HKT/SGT
Eisai Presented Latest Trends of Treatment for Alzheimer's at AAIC 2019
July 19, 2019 08:15 HKT/SGT
Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
July 18, 2019 13:26 HKT/SGT
Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019
July 18, 2019 12:01 HKT/SGT
Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019
July 17, 2019 08:20 HKT/SGT
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
July 11, 2019 12:59 HKT/SGT
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
July 11, 2019 09:04 HKT/SGT
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
July 10, 2019 12:27 HKT/SGT
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
July 8, 2019 09:31 HKT/SGT
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery
June 18, 2019 12:32 HKT/SGT
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: